Vikerfors Anders, Davidsson Sabina, Frey Janusz, Jerlström Tomas, Carlsson Jessica
Department of Urology, Faculty of Medicine and Health, Örebro University, 703 62 Örebro, Sweden.
Cancers (Basel). 2021 Nov 21;13(22):5841. doi: 10.3390/cancers13225841.
Soluble PD-L1 (sPD-L1) levels have been identified as a potential biomarker for various cancers, but its diagnostic and prognostic value in urinary bladder cancer (BC) remains to be fully elucidated. In this study, we investigated sPD-L1 levels in serum and urine samples from 132 patients with BC and compared them to 51 patients with hematuria (controls). The levels of sPD-L1 in serum and urine were determined using ELISA. Soluble PD-L1 could be detected in 99.5% of the serum samples and 34.4% of the urine samples. Patients diagnosed with BC had significantly higher urinary levels of sPD-L1, compared to controls, however no difference were found in serum sPD-L1 levels ( = 0.038 and = 0.61, respectively). Significantly higher serum sPD-L1 levels were found in patients with muscle invasive disease and metastatic disease, compared to patients with non-muscle invasive BC and non-metastatic disease ( < 0.05). There was also a trend for higher urine sPD-L1 levels in patients with metastatic disease, compared to patients with non-metastatic disease ( = 0.05). The results from this study suggest that sPD-L1 in serum, but not in urine, could be a potential prognostic biomarker for patients with BC.
可溶性程序性死亡受体配体1（sPD-L1）水平已被确定为多种癌症的潜在生物标志物，但其在膀胱癌（BC）中的诊断和预后价值仍有待充分阐明。在本研究中，我们调查了132例BC患者血清和尿液样本中的sPD-L1水平，并将其与51例血尿患者（对照组）进行比较。采用酶联免疫吸附测定法（ELISA）测定血清和尿液中的sPD-L1水平。在99.5%的血清样本和34.4%的尿液样本中可检测到可溶性PD-L1。与对照组相比，被诊断为BC的患者尿液中sPD-L1水平显著更高，然而血清sPD-L1水平未发现差异（分别为P = 0.038和P = 0.61）。与非肌层浸润性BC和非转移性疾病患者相比，肌层浸润性疾病和转移性疾病患者的血清sPD-L1水平显著更高（P < 0.05）。与非转移性疾病患者相比，转移性疾病患者的尿液sPD-L1水平也有升高趋势（P = 0.05）。本研究结果表明，血清中的sPD-L1而非尿液中的sPD-L1可能是BC患者的潜在预后生物标志物。
